Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014

...y shift the retinal treatment paradigm again. In several years, current market leaders Genentech and Novartis will face competitors such as Regeneron, sirion Therapeutics, and Neurotech Pharmaceuticals. Demand for retinal surgery is also growing rapidly, and surgical techniques are quickly evolving t...

Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide

... TAMPA, Fla., April 15 /PRNewswire/ -- sirion Therapeutics, Inc. announced today positive result... Based on the results of this interim analysis, sirion plans to continue the current study to its conclusion. sirion will meet with its scientific advisors and the FDA...

Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation

... TAMPA, Fla., Feb. 27 /PRNewswire/ -- sirion Therapeutics, Inc., a privately held ophthalmic-fo... Administration (FDA) and granted priority review. sirion Therapeutics is seeking approval from the FDA for ... in Chicago, IL. Durezol(TM) is the trademark of sirion Therapeutics Inc. and is currently under review by...

ISI Announces Expansion of Mid-Market Life Science Compliance Solutions at DIA eCTD Conference

...t to big pharma partners that may in-license a compound at a later stage." sirion Therapeutics, a ophthalmic biopharmaceutical company with a San Diego-based...As an emerging company with a relatively small regulatory operations staff, sirion needed a tool that would be easy to use and easy to expand as the company a...

WeissComm Partners Makes 10 New Hires as It Wins New Accounts and Grows Existing Business

...al device, diagnostic and pharmaceutical companies. They include Alsius Corporation, Emphasys Medical, Map Pharmaceuticals, Sagent Pharmaceuticals and sirion Therapeutics. "Given the increasing competition to retain talented healthcare communications professionals, it is gratifying to see that our entrepre...

Sirion in Medical Technology

Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain

Results from Phase 3b Studies with Durezol Dosed Prior to Surgery TAMPA, Fla., Oct. 6 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% is now commercially avai...

Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

... TAMPA, Fla., April 30 /PRNewswire/ -- sirion Therapeutics, Inc. announced today that eight pres...enretinide, and retinal research programs from the sirion San Diego, CA based drug discovery laboratory. ...this study was provided in a press release made by sirion on April 15th, 2009. The ARVO presentations on fen...

Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented

... TAMPA, Fla., Nov. 3 /PRNewswire/ -- sirion Therapeutics, Inc., a privately held ophthalmic-fo...bert E. Kaufman, M.D., Ophthalmologist Emeritus of sirion Therapeutics and formerly Professor of Ophthalmolo...r herpes," said Barry Butler, President and CEO of sirion Therapeutics, Inc. "These medications have the pot...

Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)

... TAMPA, Fla., Oct. 14 /PRNewswire/ -- sirion Therapeutics, Inc., a privately held ophthalmic-fo...xciting," noted Barry Butler, CEO and President of sirion Therapeutics. "Although this study was not designe...the consequence of the surgical procedure. About sirion Therapeutics, Inc. ...

Sirion Therapeutics Announces Positive Phase III Results for Difluprednate

...- TAMPA, Fla., Oct. 25 /PRNewswire-FirstCall/ -- sirion Therapeutics, Inc., a privately held ophthalmic-fo...ion's Chief Medical Officer. "Based on these data, sirion is moving forward with its plans to submit a New D...m as a treatment for patients with uveitis. About sirion Therapeutics, Inc. ...

Sirion Therapeutics Announces Clinical Data to be Presented at the 2007 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

... TAMPA, Fla., April 23, 2007 /PRNewswire/ -- sirion Therapeutics announced today that data on two of t...zing ophthalmic therapies for unmet needs." sirion Therapeutics Reception for all ARVO attendees: A company update and presentation by sirion Therapeutics' senior executives Date: Tu...

Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection

... TAMPA, Fla., April 16, 2007 /PRNewswire/ -- sirion Therapeutics, Inc., an ophthalmic-focused biopharm... Thea in Europe under the brand name of Virgan(R). sirion licensed the rights to Virgan(R) for the United St...al to help patients preserve their sight." About sirion Therapeutics, Inc. ...

Sirion in Biological Technology

Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA

...Uveitis TAMPA, Fla., March 16 /PRNewswire/ -- sirion Therapeutics, Inc. announced today that its supple...ed for review. Durezol, developed and marketed by sirion Therapeutics, was approved by the FDA in June 2008...of blindness in the US," said Barry Butler, CEO of sirion Therapeutics. "We are encouraged that the FDA is r...

Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health

... TAMPA, Fla., Feb. 16 /PRNewswire/ -- sirion Therapeutics, Inc., a privately held ophthalmic-fo...he-counter TheraTears(R) dry-eye product line. The sirion sales force will promote MacuTrition and the Nutri...system to help address these symptoms. About sirion Therapeutics, Inc. ...

Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes

... TAMPA, Fla., Jan. 26 /PRNewswire/ -- sirion Therapeutics, Inc., a privately held ophthalmic-fo...ew by the U.S. Food and Drug Administration (FDA). sirion Therapeutics is seeking approval for ganciclovir a...the United States," explained Barry Butler, CEO of sirion Therapeutics. "If approved by the FDA, ganciclovir...

Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain

...on and Pain TAMPA, Fla., June 24 /PRNewswire/ -- sirion Therapeutics, Inc., a privately held ophthalmic-fo...ol is a powerful option for postoperative care." sirion Therapeutics plans to make Durezol commercially av...zol for the treatment of anterior uveitis. About sirion Therapeutics, Inc. ...

Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO

... TAMPA, Fla., April 21 /PRNewswire/ -- sirion Therapeutics, Inc., a privately held ophthalmic-fo...ery team," said Barry Butler, President and CEO of sirion Therapeutics, Inc. "Sirion's targeted research app...iego, CA. [Note: Durezol(TM) is the trademark of sirion Therapeutics, Inc. and is currently under review b...

Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium

... TAMPA, Fla., April 8, 2008 /PRNewswire/ -- sirion Therapeutics, Inc., a privately held ophthalmic-fo...26, 2008 under the Prescription Drug User Fee Act. sirion is currently conducting a Phase 3 trial with Durez...the end of 2008. Durezol(TM) is the trademark of sirion Therapeutics, Inc. and is currently under review b...

Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases

... TAMPA, Fla., Feb. 20 /PRNewswire/ -- sirion Therapeutics, Inc., a privately held ophthalmic-fo...cs. Under the terms of this licensing agreement, sirion Therapeutics will have the rights to manufacture, ...09," said Barry Butler, Chief Executive Officer of sirion Therapeutics. Dr. Gunnar Aberg, Chief Executive ...

Sirion Therapeutics Supports Ophthalmic Education

... Meeting - TAMPA, Fla., Sept. 28 /PRNewswire/ -- sirion Therapeutics, Inc., a privately held ophthalmic-fo...ncing the treatment of ophthalmic disease." About sirion Therapeutics, Inc. sirion Therapeutics is a privately held biopharmaceutical...